GetTopicDetailResponse(id=aacc9223865, topicName=貝達奎寧, introduction=貝達奎寧, content=null, image=null, comments=5, allHits=1315, url=https://h5.medsci.cn/topic?id=92238, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102131, tagList=[TagDto(tagId=102131, tagName=貝達奎寧)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1412254, encodeId=2c601412254c9, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#貝達奎寧#</a>, objectTitle=含貝達奎寧的短期療程方案治療耐多藥結核病的成本效益分析, objectType=article, longId=191963, objectId=c76e19196362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c76e19196362, replyNumber=0, likeNumber=87, createdTime=2020-04-12, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c76e19196362, moduleTitle=含貝達奎寧的短期療程方案治療耐多藥結核病的成本效益分析, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=c76e19196362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412253, encodeId=5b04141225316, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#貝達奎寧#</a>, objectTitle=貝達奎寧治療耐多藥和廣泛耐藥結核：安全有效, objectType=article, longId=191934, objectId=f08b19193483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f08b19193483, replyNumber=0, likeNumber=73, createdTime=2020-04-11, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f08b19193483, moduleTitle=貝達奎寧治療耐多藥和廣泛耐藥結核：安全有效, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f08b19193483)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412252, encodeId=ec0d141225248, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#貝達奎寧#</a>, objectTitle=貝達奎寧治療耐多藥結核病的美國經(jīng)驗 , objectType=article, longId=191820, objectId=b450191820c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b450191820c1, replyNumber=0, likeNumber=86, createdTime=2020-04-10, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b450191820c1, moduleTitle=貝達奎寧治療耐多藥結核病的美國經(jīng)驗 , moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b450191820c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412251, encodeId=154e1412251d3, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#貝達奎寧#</a>, objectTitle=EUR RESPIR J：貝達奎寧治療耐多藥結核的長期??有效性和安全性, objectType=article, longId=191132, objectId=638519113241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=638519113241, replyNumber=0, likeNumber=87, createdTime=2020-04-01, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=638519113241, moduleTitle=EUR RESPIR J：貝達奎寧治療耐多藥結核的長期??有效性和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=638519113241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1412250, encodeId=24f31412250fa, content=<a href='/topic/show?id=aacc9223865' target=_blank style='color:#2F92EE;'>#貝達奎寧#</a>, objectTitle=LANCET RESP MED：貝達奎寧顯著降低耐藥結核病患者的死亡率, objectType=article, longId=191131, objectId=01741911314e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01741911314e, replyNumber=0, likeNumber=110, createdTime=2020-04-01, rootId=0, userName=liuhuangbo, userId=40a02837569, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01741911314e, moduleTitle=LANCET RESP MED：貝達奎寧顯著降低耐藥結核病患者的死亡率, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=01741911314e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
